NIH - National Institute of Neurological Disorders and Stroke

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">NIH - National Institute of Neurological Disorders and Stroke</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>NINDS Logo</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Bethesda, MD, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Government Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1950</td>
</tr>
<tr>
<td class="label">Annual Budget</td>
<td>~$2.4 billion (FY2024)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.ninds.nih.gov/" target="_blank">https://www.ninds.nih.gov/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Stroke, [FTD](/diseases/frontotemporal-dementia)</td>
</tr>
<tr>
<td class="label">Director</td>
<td>Dr. Walter J. Koroshetz</td>
</tr>
</table>

NIH - National Institute of Neurological Disorders and Stroke

Overview

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">NIH - National Institute of Neurological Disorders and Stroke</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>NINDS Logo</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Bethesda, MD, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Government Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1950</td>
</tr>
<tr>
<td class="label">Annual Budget</td>
<td>~$2.4 billion (FY2024)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.ninds.nih.gov/" target="_blank">https://www.ninds.nih.gov/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Stroke, [FTD](/diseases/frontotemporal-dementia)</td>
</tr>
<tr>
<td class="label">Director</td>
<td>Dr. Walter J. Koroshetz</td>
</tr>
</table>

NIH - National Institute of Neurological Disorders and Stroke

Overview

The National Institute of Neurological Disorders and Stroke (NINDS) is one of 27 institutes and centers that comprise the National Institutes of Health (NIH). Established in 1950, NINDS is the primary federal agency supporting research on the brain and nervous system, with an annual budget of approximately $2.4 billion["@nih2026"].

NINDS plays a pivotal role in advancing understanding, treatment, and prevention of neurological disorders, including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). The institute supports research through both intramural (internal) and extramural (external grant funding) programs, making it the largest funder of neuroscience research in the United States["@koroshartz2020"].

As part of the NIH's broader Accelerating Medicines Partnership (AMP), NINDS leads significant initiatives targeting neurodegenerative disease drug discovery and biomarker development["@collins2017"]. The institute's research portfolio spans basic science, translational research, and clinical trials, positioning it at the forefront of efforts to develop disease-modifying therapies for conditions that currently lack effective treatments.

History and Mission

Founding and Evolution

NINDS was established in 1950 as the National Institute of Neurological Diseases and Blindness, combining research on neurological disorders with vision research. In 1956, the name was changed to the National Institute of Neurological Diseases and Stroke, and later shortened to the National Institute of Neurological Disorders and Stroke. Vision research was transferred to the National Eye Institute in 1968.

Over the decades, NINDS has evolved from a small institute focused primarily on basic neuroscience to a comprehensive research agency addressing the full spectrum of neurological disorders. The institute's mission has expanded to include:

• Supporting research on causes, prevention, and treatment of neurological disorders
• Training the next generation of neuroscientists and clinical researchers
• Disseminating research findings to the scientific community and public
• Facilitating translation of basic discoveries into clinical applications

Strategic Priorities

NINDS's current strategic plan for neurodegenerative disease research emphasizes[@koroshetz2020]:

Research Programs

Alzheimer's Disease Research

NINDS supports a comprehensive portfolio of Alzheimer's disease research[@parker2020][@scheltens2016]:

Basic Research:

• Amyloid-beta and tau biology
• Neuroinflammation and glial contributions
• Synaptic dysfunction and neuronal loss
• Genetic risk factors (APOE, TREM2, etc.)

• Drug target validation
• Biomarker development
• Animal model development
• Preclinical drug testing

• Clinical trials infrastructure support
• Biomarker validation studies
• Prevention trials in at-risk populations
• Care intervention research

Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD)

NINDS is a key partner in the AMP-AD initiative, a public-private partnership that aims to identify and validate novel therapeutic targets[@collins2017]:

• Multi-omics analysis of human brain tissue
• Systems biology approaches to target identification
• Open data sharing through the AMP-AD Knowledge Portal
• Consortium of academic and industry partners

Parkinson's Disease Research

NINDS supports extensive Parkinson's disease research[@kalia2021]:

Key Programs:

• Parkinson's Progression Marker Initiative (PPMI): Landmark longitudinal study establishing biomarkers and progression markers[@marek2019]
• Parkinson's Disease Biomarkers Program: Developing fluid and imaging biomarkers
• NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research: Specialized research centers

• Alpha-synuclein biology and aggregation
• LRRK2 and GBA genetics
• Mitochondrial dysfunction
• [Neuroinflammation](/mechanisms/neuroinflammation) Circuit dysfunction and deep brain stimulation

ALS and Frontotemporal Dementia

NINDS supports research on ALS and FTD, which share overlapping mechanisms[@taylor2019]:

Research Portfolio:

• C9orf72 repeat expansion biology
• TDP-43 proteinopathy
• RNA metabolism defects
• Excitotoxicity
• Axonal transport dysfunction

• SOD1 targeting therapies
• Antisense oligonucleotide approaches
• Neuroprotective agents
• Cell replacement strategies

Stroke Research

NINDS is a major funder of stroke research[@singh2016]:

Program Areas:

• Acute stroke treatment (tPA, thrombectomy)
• Stroke prevention
• Rehabilitation and recovery
• Vascular cognitive impairment
• Small vessel disease

• NIH StrokeNet: Clinical trials network
• Stroke Prevention Interventions Research Network

Funding Programs

Grant Mechanisms

NINDS provides funding through various mechanisms:

| Mechanism | Purpose | Typical Award Size |
|-----------|---------|-------------------|
| R01 | Research Project Grant | $250-500K/year |
| R21 | Exploratory/Developmental | $100-200K/year |
| R35 | Research Program Award | $1-2M/year |
| U01 | Cooperative Agreement | Varies |
| P50 | Specialized Center | $2-5M/year |
| K99/R00 | Career Transition Award | $250K+ |
| F31/F32 | Fellowships | $30-50K/year |

Specialized Programs

Udall Centers of Excellence
The NINDS Udall Centers program funds comprehensive Parkinson's disease research centers across the United States. Each center brings together basic, translational, and clinical researchers to accelerate progress toward new treatments.

NINDS Alzheimer Disease Research Centers
These centers conduct innovative research on Alzheimer's disease and related disorders, with emphasis on early detection, treatment, and prevention.

Clinical Trials Infrastructure
NINDS supports clinical trial infrastructure through[@sims2019]:

• Clinical Trials Methodology Development
• Clinical Trial Readiness in Alzheimer's Disease
• NINDS Clinical Trials Network

Training and Career Development

Training Programs

NINDS supports training through multiple mechanisms[@holder2020]:

Predoctoral Training:

• F31 Ruth L. Kirschstein National Research Service Award
• Institutional training grants (T32)
• Combined MD/PhD programs

• F32 Fellowships
• K99/R00 Career Transition Award
• Intramural Training Program

• Neurology residency programs
• Clinical fellowship support
• Clinical investigator awards

Career Development

NINDS supports career progression through:

• K08 Clinical Investigator Award: Mentored research development
• K23 Patient-Oriented Research Award: Clinical research training
• K24 Midcareer Investigator Award: Mentored patient-oriented research
• K99/R00 Pathway to Independence: Transition to independence

Key Initiatives

Accelerating Medicines Partnership (AMP)

NINDS participates in AMP programs for:

• AMP-AD: Alzheimer's Disease
• AMP-PD: Parkinson's Disease
• AMP-MS: Multiple Sclerosis

NIH StrokeNet

NINDS coordinates NIH StrokeNet, a national network conducting multi-site clinical trials for stroke prevention, treatment, and recovery[@singh2016].

International Collaboration

NINDS collaborates with international partners:

• European Union Joint Programme - Neurodegenerative Disease Research (JPND)
• International Parkinson's Disease Genomics Consortium
• International Alzheimer's Disease Research Consortium

Rare Disease Research

NINDS supports research on rare neurological diseases[@siegal2022]:

• Lysosomal storage disorders affecting the nervous system
• Rare genetic forms of neurodegenerative disease
• Pediatric neurodegenerative conditions

Intramural Research

NINDS conducts internal (intramural) research at the NIH campus in Bethesda:

Laboratories and Branches

• Laboratory of Neurogenetics: Genetic basis of neurological disorders
• Cellular and Molecular Neuroscience Section: Basic mechanisms
• Clinical Investigations: Human subject research
• Brain Stimulation Unit: Novel therapeutic approaches

Clinical Programs

• NINDS Movement Disorders Fellowship: Clinical training
• Cognitive Neuroscience Program: Memory and aging research
• Neurocritical Care Program: Acute brain injury research

Data Resources and Infrastructure

NINDS supports several major data resources:

| Resource | Description | Access |
|----------|-------------|--------|
| AMP-AD Knowledge Portal | Multi-omics data | Open |
| PPMI Data | Parkinson's biomarker data | Open |
| NIH Blueprint | Neuroscience tools | Open |
| NINDS Biofluid Bank | Biospecimens | Request |

Biobank and Biospecimens

NINDS maintains repositories of biospecimens for research:

• Brain tissue bank
• CSF samples
• DNA and RNA
• Patient-derived cells

Impact and Achievements

Scientific Advances

NINDS-funded research has contributed to major advances:

Translation Successes

• Multiple FDA-approved therapies traceable to NINDS-funded research
• Biomarkers validated for clinical use
• Novel therapeutic targets advanced to clinical testing

Future Directions

Strategic Priorities 2025-2030

NINDS's future research directions include:

Emerging Programs

• AI/ML for Drug Discovery: Machine learning approaches
• Cellular Models: iPSC-based screening platforms
• Neuroprotection: Broad-spectrum neuroprotective strategies

Cross-Links and Related Content

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Stroke](/diseases/ischemic-stroke)

Related Proteins

• [Amyloid Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [TDP-43](/proteins/tdp43)

Related Genes

• [APP](/genes/app)
• [PSEN1](/genes/psen1)
• [LRRK2](/genes/lrrk2)
• [GBA](/genes/gba)
• [SNCA](/genes/snca)

Related Mechanisms

• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Biomarkers](/biomarkers/overview)

Related Institutions

• [National Institutes of Health](/institutions/nih)
• [National Institute on Aging](/institutions/nih-nia)
• [Michael J. Fox Foundation](/institutions/michael-j-fox-foundation)
• [Alzheimer's Association](/institutions/alzheimers-association)

References